None listed
Conditions
Interventions
Group I: 5.75 mg of camostat mesylate and 394.25 mg of lactose as excipients are dissolved in a 100ml Tap water and wash the mouth 4 times a day for 56 days.
Group II: Dissolve only 400 mg of lactose
Sponsors
Nishizaki Yasuriro
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1.Gender: Any 2.Age: 20 and over, under 75 3. Independent living possible person 4.Persons who can reliably answer questions, measure body temperature, and observe health 5.Persons who understand this research and complete the consent form 6.Persons who have been confirmed negative by PCR test
Exclusion criteria
Exclusion criteria: 1.Persons who do not meet the selection criteria 2.Persons who have been infected with SARS-CoV-2 within 3 months 3.Persons who have had close contact with SARS-CoV-2 infected persons within 2 weeks 4.Persons who are taking Camostat Mesilate tablets due to chronic pancreatitis, etc. 5.Persons who are at risk of developing allergies related to this study 6.Persons with symptoms such as fever, sore throat, cough, dysgeusia, olfactory sensation, and diarrhea within 3 weeks 7.Persons who are currently participating in some clinical trial or who participated within 2 months before the start of the trial 8.Persons who are judged to be unsuitable by the principal investigator and the investigators
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARS-CoV-2 PCR test | — |
Secondary
| Measure | Time frame |
|---|---|
| Age, gender, life history (question),Blood biochemical test, Chest CT(if perfomed) | — |
Contacts
Public ContactYasuhiro Nishizaki
Tokai University Tokyo Hospital
Outcome results
None listed